• MS Does Not Excuse Poor Behavior
  • Publication of Phase 3 Trial Results Supports FDA Approval of Copiktra, Verastem Announces
  • Study Identifies Predictors of Poor Outcome in Patients with SSc at Risk for Pulmonary Hypertension
  • Cerdelga May Be a Cost-saving Treatment Option for Gaucher Type 1, Study Finds
  • Data from PHAROS Trial Reveals Danger of Poorer Outcomes for Scleroderma Patients At-Risk of PH
  • #ECTRIMS2018 – Shifting from Gilenya to Lemtrada Doesn’t Increase Risk of MS Reactivation, Study Says
  • A Half-empty Glass
  • Let’s Treat Ourselves with Kindness
  • On Turning 25
  • Wheelchair-accessible Halloween Happenings
  • Hey, CF Caregivers, Your Loving Words Help Us Survive
  • Traveling Challenges and Tips to Consider